TICKERNOMICS Sign up
Last Update: 2024-03-28 02:16:28
Aptose Biosciences Inc ( APS.TO ) https://www.aptose.com
1.51USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-84.70%
APS.TO
SPY
32.74%
-98.29%
APS.TO
SPY
92.93%
-94.99%
APS.TO
SPY
224.41%
-98.43%
APS.TO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11.70
10.22
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.26
0.00
2.03
-687.73
0.00
-0.22
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.0373
-192.41
-156.42
1.01
Other Earnings and Cash Flow Stats:
Aptose Biosciences Inc ( APS.TO ) Net Income TTM ($MM) is -40.63
Aptose Biosciences Inc ( APS.TO ) Operating Income TTM ($MM) is -43.46
Aptose Biosciences Inc ( APS.TO ) Owners' Earnings Annual ($MM) is 0.00
Aptose Biosciences Inc ( APS.TO ) Current Price to Owners' Earnings ratio is 0.00
Aptose Biosciences Inc ( APS.TO ) EBITDA TTM ($MM) is -43.00
Aptose Biosciences Inc ( APS.TO ) EBITDA Margin is 0.00%
Capital Allocation:
Aptose Biosciences Inc ( APS.TO ) has paid 0.00 dividends per share and bought back 84.724 million shares in the past 12 months
Aptose Biosciences Inc ( APS.TO ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Aptose Biosciences Inc ( APS.TO ) Interest-bearing Debt ($MM) as of last quarter is 0
Aptose Biosciences Inc ( APS.TO ) Annual Working Capital Investments ($MM) are 12
Aptose Biosciences Inc ( APS.TO ) Book Value ($MM) as of last quarter is 5
Aptose Biosciences Inc ( APS.TO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Aptose Biosciences Inc ( APS.TO ) has 1 million in cash on hand as of last quarter
Aptose Biosciences Inc ( APS.TO ) has 9 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aptose Biosciences Inc ( APS.TO ) has 7 common shares outstanding as of last quarter
Aptose Biosciences Inc ( APS.TO ) has 0 million USD of preferred stock value
Academic Scores:
Aptose Biosciences Inc ( APS.TO ) Altman Z-Score is -42.51 as of last quarter
Aptose Biosciences Inc ( APS.TO ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Aptose Biosciences Inc ( APS.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Aptose Biosciences Inc ( APS.TO ) for the amount of $ on
9.94% of Aptose Biosciences Inc ( APS.TO ) is held by insiders, and 14.27% is held by institutions
Aptose Biosciences Inc ( APS.TO ) went public on 1970-01-01
Other Aptose Biosciences Inc ( APS.TO ) financial metrics:
FCF:-53.67
Unlevered Free Cash Flow:-55.74
EPS:-4.58
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-599.53
Beta:1.01
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aptose Biosciences Inc ( APS.TO ) :
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.